🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. JS004

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. JY231 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  3. JZP541

    Jazz Pharmaceuticals Ireland Limited

    Irritability Associated With Autism Spectrum Disorder

    phase 2 small molecule terminated

    1 trial

  4. JZP598

    Ningbo Cancer Hospital

    Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, colorectal, head & neck or sarcoma) or HER2 mutant non-small cell lung cancer.

    phase 2 small molecule active

    1 trial

  5. Jardiance 10 mg film-coated tablets, BI 690517, Spironolacton Accord 25 mg filmomhulde tabletten, OMNIPAQUE 350 mg I/ml., AMINOHIPPURIC ACID

    Disc Medicine

    Heart failure, cardiovascular disease, chronic kidney disease

    phase 2 small molecule active

    1 trial

  6. Jiangtang Tiaozhi recipe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type2 Diabetes

    phase 2 small molecule active

    1 trial

  7. Jintrolong® low dose group

    The First People's Hospital of Lianyungang

    Dwarfism

    phase 2 small molecule active

    1 trial

  8. Jueyin granules

    The First People's Hospital of Lianyungang

    Psoriasis Vulgaris

    phase 2 small molecule active

    1 trial

  9. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    Squamous cell carcinoma of vulva/vagina, Squamous cell carcinoma of the head and neck, Squamous cell carcinoma of penis, Squamous cell carcinoma of cervix, Squamous cell carcinoma of anus

    phase 2 small molecule active

    1 trial

  10. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., FLUOROURACIL, CAPECITABINE BIOGARAN 500 mg, comprimé pelliculé, Avastin 25 mg/ml concentrate for solution for infusion., OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE

    phase 2 small molecule active

    1 trial

  11. KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , GEMCITABINE , PACLITAXEL , FAMOTIDINE , MK-2870, PARACETAMOL , CISPLATIN , PEMETREXED , -, -

    Merck Sharp and Dohme

    Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  12. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan Baxter 50 mg Compresse rivestite

    Istituto Gentili S.r.l.

    Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall

    phase 2 small molecule active

    1 trial

  13. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CISPLATIN , CARBOPLATIN

    Istituto Gentili S.r.l.

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  14. KEYTRUDA 25 mg/mL concentrate for solution for infusion, TEDOPI

    Ningbo Cancer Hospital

    Platinum sensitive recurrent ovarian cancer

    phase 2 small molecule active

    1 trial

  15. KEYTRUDA 25 mg/mL concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion.

    Ningbo Cancer Hospital

    METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)

    phase 2 small molecule active

    1 trial

  16. KEYTRUDA 25 mg/mL concentrate for solution for infusion., PARACETAMOL , CISPLATIN , FLUOROURACIL , -, MK-2870, CALCIUM FOLINATE , CALCIUM LEVOFOLINATE , -, MK-2870, -

    Merck Sharp and Dohme

    Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  17. KN046

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  18. Kanglaite

    The First People's Hospital of Lianyungang

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  19. Karelizumab combined with etoposide and cisplatin

    Jian Li

    Carcinoma

    phase 2 small molecule active

    1 trial

  20. Kenacort-A 40, suspensie voor injectie 40 mg/ml, JNJ-81201887, Placebo to match Prednisone 20mg, 5mg, JNJ-81201887, Prednison acis 20 mg, Tabletten, Prednison acis 5 mg, Tabletten

    Janssen-Cilag International N.V.

    Geographic Atrophy

    phase 2 small molecule active

    1 trial

  21. LB-100

    LIXTE BIOTECHNOLOGY HOLDINGS, INC.

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  22. LB-208, LB-208

    AOP Orphan Pharmaceuticals GmbH

    Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

    phase 2 small molecule active

    1 trial

  23. LB1410

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  24. LBL-024 for Injection

    The First People's Hospital of Lianyungang

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources